• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

FDA accepts NDA for long-acting testosterone drug

Article

The FDA has accepted Indevus Pharmaceuticals’ new drug application for its long-acting depot preparation of testosterone undecanoate (Nebido) for the treatment of male hypogonadism. The NDA is predicated on data from six clinical studies in which more than 400 patients received at least one dose of the drug, more than 300 of whom were treated for more than 1 year.

The FDA has accepted Indevus Pharmaceuticals’ new drug application for its long-acting depot preparation of testosterone undecanoate (Nebido) for the treatment of male hypogonadism. The NDA is predicated on data from six clinical studies in which more than 400 patients received at least one dose of the drug, more than 300 of whom were treated for more than 1 year.

In total, more than 3,000 injections of the formulation have been given to hypogonadal males during the clinical development program, according to the company. The application includes post-marketing data from safety reporting through June 2007, reflecting the world-wide experience from more than 260,000 injections of the drug.

Related Videos
Blurred interior of hospital |  Image Credit: © jakkapan - stock.adobe.com
Laura Bukavina, MD, MPH, answers a question during a Zoom video interview
Image of kidneys | Image Credit: © peterschreiber.media - stock.adobe.com
Neal Shore, MD, FACS, and Brian M. Shuch, MD, experts on kidney cancer
Neal Shore, MD, FACS, and Brian M. Shuch, MD, experts on kidney cancer
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.